Retatrutide vs Tirzepatide: Weight Loss, Muscle Loss, Side Effects & Dosage Chart (2026)

- October 24, 2026

Last reviewed: October 2026

Retatrutide and tirzepatide are investigational and established approaches to incretin-based weight management, respectively. Both act on the GLP-1 and GIP pathways, but retatrutide also activates the glucagon receptor. Their overlapping mechanisms make them scientifically related, but their clinical status, evidence base, and dosing are not interchangeable.

Retatrutide has produced substantial weight loss in Phase 3 trials, including a published trial in which the 12 mg group lost an average of 25.0% of baseline body weight over 80 weeks using the treatment-regimen estimand. Tirzepatide produced an average reduction of 20.9% with its 15 mg dose over 72 weeks in SURMOUNT-1. These are results from separate trials, not a head-to-head comparison.

Important: Retatrutide remains investigational and is not approved for public use as of October 24, 2026. Tirzepatide has approved uses in relevant jurisdictions. Do not combine retatrutide and tirzepatide or use products sold as research chemicals outside a legitimate clinical trial.

Quick comparison: retatrutide vs tirzepatide

Feature	Retatrutide	Tirzepatide
Receptor targets	GIP, GLP-1 and glucagon	GIP and GLP-1
Drug generation	Triple agonist	Dual agonist
Administration in trials	Once-weekly subcutaneous injection	Once-weekly subcutaneous injection
Published pivotal obesity trial	TRIUMPH-1: 80 weeks	SURMOUNT-1: 72 weeks
Reported average weight reduction at highest studied dose in the cited trial	25.0% at 12 mg, using the treatment-regimen estimand	20.9% at 15 mg, using the treatment-regimen estimand
Muscle preservation	Lean mass decreases were observed in a Phase 2 body-composition substudy	Lean mass decreases were observed in a DXA substudy
Common side effects	Nausea, diarrhea, constipation, vomiting; altered skin sensation was also reported	Nausea, diarrhea, vomiting, constipation and abdominal symptoms
Regulatory status	Investigational; not approved for public use	Approved for specific indications in relevant jurisdictions
Can they be taken together?	No established safe or effective combination; do not stack these medications.

Interpretation: The published average weight-loss percentages do not prove that retatrutide is superior to tirzepatide. Trial duration, participant characteristics, analysis methods, and treatment discontinuation can influence results. Reference: TRIUMPH-1 and SURMOUNT-1.

1. How do retatrutide and tirzepatide work?

Tirzepatide: a dual GIP/GLP-1 receptor agonist

Tirzepatide activates two hormone receptors involved in metabolic regulation:

GLP-1 receptor: helps regulate appetite, food intake, insulin secretion and gastric emptying.
GIP receptor: contributes to glucose regulation and interacts with the body's metabolic response to food.

These actions can reduce hunger, improve glucose regulation and support sustained weight loss when combined with appropriate nutrition and physical activity. Tirzepatide is marketed under different brand names depending on the indication and country, including Zepbound for chronic weight management in the United States.

Retatrutide: a triple GIP/GLP-1/glucagon receptor agonist

Retatrutide activates the same two receptor pathways as tirzepatide and adds the glucagon receptor. This additional activity may affect energy expenditure, liver metabolism and fat utilization.

The three-receptor mechanism is a plausible reason to investigate whether retatrutide can produce greater weight reduction. However, a plausible mechanism does not independently establish superior long-term clinical outcomes, cardiovascular safety or better preservation of muscle.

Retatrutide is being evaluated in Phase 3 clinical trials. Its dose, long-term safety profile and appropriate indications remain subject to clinical and regulatory evaluation.

2. Which produces more weight loss?

The most informative current comparison uses the published Phase 3 TRIUMPH-1 results for retatrutide and the published Phase 3 SURMOUNT-1 results for tirzepatide. Both trials enrolled adults with obesity or overweight without diabetes, although their specific eligibility criteria and populations were not identical.

Retatrutide: TRIUMPH-1, 80 weeks

The Phase 3 TRIUMPH-1 trial, published in The New England Journal of Medicine in September 2026, randomized 2,339 participants to retatrutide 4 mg, 9 mg or 12 mg, or placebo. The reported mean changes in body weight using the treatment-regimen estimand were:

Study group	Mean weight change at week 80
Retatrutide 4 mg	−17.6%
Retatrutide 9 mg	−23.7%
Retatrutide 12 mg	−25.0%
Placebo	−3.9%

The sponsor also publicized an efficacy-estimand result of 28.3% average weight loss at 12 mg. This is a different analysis from the treatment-regimen estimate above; the figures should not be presented as interchangeable. Analysis methods matter when comparing headline numbers.

Source: TRIUMPH-1 peer-reviewed report and Lilly's Phase 3 announcement.

Tirzepatide: SURMOUNT-1, 72 weeks

In SURMOUNT-1, adults with obesity or overweight and at least one weight-related complication, without diabetes, received tirzepatide or placebo alongside lifestyle intervention. Mean weight changes at week 72 were:

Study group	Mean weight change at week 72
Tirzepatide 5 mg	−15.0%
Tirzepatide 10 mg	−19.5%
Tirzepatide 15 mg	−20.9%
Placebo	−3.1%

Source: Tirzepatide once weekly for the treatment of obesity, NEJM.

Why the numbers are not a direct ranking

The numerical difference is interesting, but the two studies did not randomize the same participants to retatrutide versus tirzepatide. Retatrutide's pivotal trial also ran for eight weeks longer.

The Phase 3 TRIUMPH-5 trial was designed specifically to compare retatrutide with tirzepatide in adults with obesity. As of October 24, 2026, the registry had no study results posted, and primary completion was estimated for November 2026. Until results are reported and evaluated, claims that one medication is definitively superior remain premature.

Source: ClinicalTrials.gov: TRIUMPH-5.

What about people with type 2 diabetes?

Weight loss tends to be lower in people with type 2 diabetes than in many obesity-trial populations without diabetes. In the Phase 3 TRIUMPH-2 trial, retatrutide produced mean weight reductions of up to 20.8% at 80 weeks, depending on dose, in participants with type 2 diabetes and obesity or overweight.

These results should be compared with diabetes-specific tirzepatide evidence rather than assuming that results in participants without diabetes apply equally to everyone.

Source: TRIUMPH-2, The Lancet, 2026.

3. Retatrutide vs tirzepatide for muscle loss

For many people, the objective of weight-loss treatment is not simply to reach a lower number on the scale. It is to reduce excess body fat while preserving skeletal muscle, strength, physical function and long-term metabolic health.

Both medications can reduce lean mass as body weight falls. The amount varies by individual, the total weight lost, nutritional intake, exercise, age, illness and other factors.

What the tirzepatide body-composition study found

A DXA substudy of SURMOUNT-1 examined 160 participants with body-composition measurements at baseline and week 72. In the pooled tirzepatide groups, the reported changes were:

Measure	Change at week 72
Body weight	−21.3%
Fat mass	−33.9%
Lean mass	−10.9%
Approximate share of weight lost from fat	75%
Approximate share of weight lost from lean mass	25%

These findings are useful, but the substudy was relatively small compared with the parent trial. DXA-derived lean mass is not synonymous with skeletal muscle. It includes non-fat soft tissues, including water-containing tissues, and does not independently measure strength or muscle function.

Source: Body composition changes during weight reduction with tirzepatide in SURMOUNT-1, 2025.

What the retatrutide body-composition study found

A Phase 2 DXA substudy studied retatrutide in people with type 2 diabetes. Over 36 weeks, higher-dose groups experienced substantial reductions in fat mass and lean mass. Exploratory analyses reported lean-mass reductions of approximately 6.5 kg in an 8 mg group and 6.4 kg in a 12 mg group.

In this substudy, lean mass accounted for approximately 38% of total weight loss in the higher-dose groups. The investigators concluded that the proportion of lean mass lost relative to weight loss was broadly similar to that seen with other obesity treatments. The study did not establish that retatrutide causes more muscle loss than tirzepatide.

Important limitations include the small number of participants with completed DXA measurements, the 36-week assessment period, the inclusion of people with diabetes, and the exploratory nature of body-composition outcomes. These results cannot be used as a direct comparison with SURMOUNT-1.

Source: Effects of retatrutide on body composition in people with type 2 diabetes, The Lancet Diabetes & Endocrinology, 2025.

Does retatrutide cause more muscle loss?

There is not enough direct comparative evidence to answer this definitively. The approximately 25% lean-mass share reported in the tirzepatide DXA substudy and the approximately 38% share in the retatrutide substudy come from different trials, populations, assessment periods and analyses.

It would be misleading to interpret those percentages as proof that retatrutide causes a specific additional amount of muscle loss. The more defensible conclusion is that both medications can be accompanied by lean-mass loss and that greater overall weight loss makes active muscle-preservation strategies particularly important.

How to help preserve muscle during weight loss

Prioritize adequate protein: Set an individualized daily protein target with a dietitian or clinician, especially if you are older, have a low appetite, or have kidney disease. Do not assume the highest possible protein intake is appropriate for everyone.
Perform progressive resistance training: Train major muscle groups regularly, with a plan adjusted for fitness, mobility, recovery and any medical limitations.
Avoid excessive energy restriction: Rapid weight loss combined with very low food intake can make it harder to meet protein and micronutrient needs.
Monitor function as well as weight: Track strength, exercise tolerance, mobility and physical function. A falling scale weight does not tell you whether muscle is being adequately preserved.
Seek help for persistent poor intake: Repeated vomiting, inability to eat enough, dehydration or marked weakness warrants prompt clinical assessment.

These principles are relevant to both drugs. There is currently no convincing evidence that adding the third receptor action in retatrutide eliminates the risk of lean-mass loss.

4. Side effects: retatrutide vs tirzepatide

Common gastrointestinal effects

Both medications act on pathways that influence appetite and gastrointestinal function. Nausea, diarrhea, constipation and vomiting are among the most common adverse effects. These symptoms often occur during dose escalation and may interfere with hydration, food intake and adherence.

The frequency of adverse events depends on the dose, the study population, the dose-escalation schedule, the duration of follow-up and the way events are collected. Percentages from different trials should not be treated as a direct safety ranking.

Retatrutide Phase 3 safety findings

In TRIUMPH-2, a trial involving participants with type 2 diabetes and obesity or overweight, several adverse events became more frequent at higher target doses:

Adverse event	4 mg	9 mg	12 mg	Placebo
Diarrhea	27.4%	33.5%	33.6%	13.2%
Nausea	13.7%	20.8%	28.0%	8.0%
Constipation	14.0%	16.2%	16.8%	9.4%
Vomiting	5.5%	10.2%	15.7%	4.2%

TRIUMPH-2 also reported hypotension and dysesthesia more frequently in retatrutide-treated groups than in the placebo group. Dysesthesia describes unusual sensations, such as tingling, burning, prickling or altered skin sensitivity. The clinical significance, predictors and long-term implications of these findings require continued study.

Source: TRIUMPH-2, The Lancet, 2026.

Tirzepatide side effects and risks

Reported adverse effects include:

Nausea, diarrhea, constipation and vomiting.
Abdominal discomfort, indigestion, belching and other digestive symptoms.
Reduced appetite and possible difficulty consuming adequate calories or protein.
Dehydration, which can contribute to kidney problems, particularly with persistent vomiting or diarrhea.
Gallbladder problems and acute pancreatitis, which require clinical evaluation if suspected.
Hypoglycemia, especially when used with insulin or insulin-secretagogue medicines such as sulfonylureas.
Delayed gastric emptying, relevant to people with significant gastrointestinal motility disorders and to anesthesia or deep-sedation planning.

The US Zepbound prescribing information includes a boxed warning about thyroid C-cell tumors observed in rodents and contraindicates use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It is not known whether this rodent finding predicts the same risk in humans. Local prescribing information should be checked for the specific product and jurisdiction.

Source: US FDA Zepbound prescribing information.

Warning signs that need urgent medical attention

Seek urgent medical advice for persistent severe abdominal pain, particularly if it radiates to the back; repeated vomiting or inability to keep fluids down; markedly reduced urination or fainting; jaundice or severe upper-abdominal pain; or signs of a severe allergic reaction. New or worsening weakness, significant tingling or altered sensation also warrants assessment rather than an assumption that it is a harmless expected effect.

Because retatrutide remains investigational, its long-term safety profile and prescribing precautions are not yet equivalent to those of an approved medicine.

5. Can retatrutide and tirzepatide be taken together?

No. Do not combine retatrutide with tirzepatide outside a specifically authorized clinical research protocol.

There is no established clinical evidence that taking both together produces better long-term weight loss, preserves muscle, or improves health outcomes compared with using one appropriate treatment. There is also no validated combined dose or established safety protocol for the pair.

The concerns include:

Overlapping GLP-1 activity: Both drugs activate the GLP-1 receptor. Tirzepatide's prescribing information does not recommend coadministration with other GLP-1 receptor agonists.
Potentially compounded gastrointestinal effects: Nausea, vomiting, diarrhea and poor oral intake could become more difficult to manage.
Dehydration and associated complications: Persistent gastrointestinal symptoms can contribute to low blood pressure and kidney injury.
Uncertain combined cardiovascular and metabolic effects: There is no approved combination protocol to define the risks, interactions or dose adjustments.
Uncertain effects on lean mass: There is no clinical evidence that combining the drugs protects muscle. Greater appetite suppression could make adequate nutrition more difficult.

People already taking tirzepatide who are considering another treatment should discuss their options with the prescribing clinician. Switching should be planned by a qualified healthcare professional; do not overlap drugs, double doses or determine a washout period from an online protocol.

6. Dosage chart: approved tirzepatide vs investigational retatrutide

The following charts distinguish the approved US tirzepatide schedule from the target doses studied in retatrutide trials. They are not interchangeable dosing schedules.

Tirzepatide: US weight-management dosing

Stage	Weekly dose	Explanation
Weeks 1–4	2.5 mg	Starting dose to improve tolerability; not a maintenance dose.
Week 5 onward, if prescribed	5 mg	First recommended maintenance option for weight management.
Further escalation, if appropriate	7.5 mg, then 10 mg	Dose increases are made in 2.5 mg increments after at least four weeks at the current dose.
Further escalation, if appropriate	12.5 mg, then 15 mg	Maintenance options for weight management include 10 mg and 15 mg; maximum recommended dose is 15 mg weekly.

The approved maintenance doses for chronic weight management in the US are 5 mg, 10 mg or 15 mg once weekly. Not everyone needs the maximum dose. Dose escalation depends on tolerability, treatment response and clinical judgment. Product indications, available strengths and local instructions may differ outside the US.

Source: US FDA Zepbound prescribing information.

Retatrutide: doses studied in Phase 3 trials

Retatrutide does not have an approved public-use dosing schedule as of October 24, 2026. The target doses below describe clinical research regimens, not instructions for self-administration.

Phase 3 trial target	Protocol approach	Important limitation
4 mg weekly	Trials initiated at 2 mg weekly, with a stepwise increase to the target dose.	Research protocol only.
9 mg weekly	Trials initiated at 2 mg weekly and used stepwise escalation through intermediate doses.	Escalation timing and protocol must not be copied as an individual regimen.
12 mg weekly	Trials initiated at 2 mg weekly and used stepwise escalation through intermediate doses.	Not an approved maintenance dose for consumers.

In the documented TRIUMPH-2 and TRIUMPH-3 protocols, participants started at 2 mg once weekly and increased doses in steps spaced four weeks apart until reaching their assigned target. The precise escalation path varied with the assigned dose and study protocol.

Do not use this information to prepare, purchase, measure or inject retatrutide. Products advertised online as retatrutide may not contain the stated ingredient or concentration and can have unknown contaminants. The legitimate route for access is participation in an authorized clinical trial.

Sources: Lilly's retatrutide information page and TRIUMPH-5 trial registry.

7. Which drug is better for different goals?

Goal or situation	Evidence-based interpretation
Choose an available, established medicine	Tirzepatide may be an option for eligible patients when approved and prescribed for the relevant indication.
Explore the potential for greater weight loss	Retatrutide's Phase 3 results are promising, but it remains investigational and head-to-head results are not yet available.
Preserve muscle	There is no proven winner. Nutrition, resistance training, adequate recovery and monitoring matter with either treatment.
Minimize adverse effects	Individual tolerability varies. Retatrutide's safety profile is still being characterized; no definitive comparative safety ranking is available.
Take both to accelerate weight loss	Not recommended. There is no established safe or effective combined regimen.

8. Evidence limitations and pharmaceutical funding

Evidence should be interpreted in context rather than ranked by the largest percentage in a headline.

Different study populations: Results in people without diabetes may not translate directly to people with type 2 diabetes or other medical conditions.
Different treatment durations: An 80-week result cannot be compared as if it were measured at the same time point as a 72-week result.
Different estimands: Treatment-regimen and efficacy estimands answer different questions about how trial data are analyzed.
Body-composition limitations: DXA-derived lean mass is not a direct measure of skeletal muscle strength, quality or function.
Sponsor funding: The pivotal retatrutide program and cited tirzepatide studies have pharmaceutical-company involvement. This does not automatically invalidate randomized trials, but sponsorship, author disclosures, trial methods and independent replication should be considered when evaluating claims.

The most important next step for the comparison is the publication of direct retatrutide-versus-tirzepatide evidence. A useful future analysis should assess not only total weight reduction, but also fat mass, lean mass, strength, treatment discontinuation, adverse effects, quality of life and long-term clinical outcomes.

Frequently asked questions

Is retatrutide stronger than tirzepatide?

Retatrutide produced larger average weight reductions in its published Phase 3 obesity trial than tirzepatide did in SURMOUNT-1. However, those are cross-trial comparisons, not proof of superiority. The head-to-head TRIUMPH-5 trial is designed to answer the question more directly.

Does retatrutide cause less muscle loss than tirzepatide?

That has not been established. A retatrutide body-composition substudy and a tirzepatide DXA substudy both found decreases in lean mass. Their results cannot be compared reliably as if the participants had been randomized to one drug or the other.

Can I take retatrutide with tirzepatide for faster results?

No. There is no established safe or effective dosing strategy for the combination. Do not stack the drugs or overlap them without authorization within a legitimate research protocol.

What is the maximum approved retatrutide dose?

There is no approved public-use retatrutide dose as of October 24, 2026. Doses such as 4 mg, 9 mg and 12 mg are target doses used in clinical trials and should not be interpreted as prescribing guidance.

What is the usual tirzepatide starting dose for weight management?

Under the US Zepbound prescribing information, the starting dose is 2.5 mg injected once weekly for four weeks, followed by 5 mg weekly. Further increases may be made in 2.5 mg increments after at least four weeks at the current dose, up to a maximum of 15 mg weekly. A clinician determines the appropriate regimen for the individual.

Can resistance training prevent all muscle loss during treatment?

No. Resistance training and adequate nutrition can help support muscle and function, but they cannot guarantee complete preservation of lean mass during substantial weight loss. Monitor strength and physical function, not just body weight.

Will retatrutide become available to the public?

Availability depends on successful completion of clinical development and regulatory review. As of October 24, 2026, retatrutide remained investigational. The development timeline is not a guarantee of approval or a confirmed public launch date.

Conclusion

Retatrutide and tirzepatide are promising but distinct approaches to treating obesity. Retatrutide's three-receptor mechanism and Phase 3 results make it an important investigational candidate, while tirzepatide has an established clinical evidence base and approved uses in relevant jurisdictions.

Neither should be viewed as a fat-loss drug that automatically protects muscle. Both can be accompanied by lean-mass loss, and the evidence does not yet establish which is better for muscle preservation. Taking the two together is not recommended.

For eligible patients considering treatment now, the practical decision should center on an approved medication, medical history, tolerability, nutritional adequacy, physical function and a sustainable plan for preserving muscle. Retatrutide's eventual role should be judged by direct comparative trials and long-term clinical outcomes, not by receptor count or headline weight-loss percentages alone.

References

Medical disclaimer: This article is for educational purposes and is not a substitute for medical advice, diagnosis or treatment. Prescription medicines should be used under appropriate clinical supervision. Retatrutide must not be sourced or used outside authorized clinical research while it remains investigational.